

Pharmaceutical Management Agency

# Section H Update for Hospital Pharmaceuticals

Effective 1 December 2018



# Contents

Summary of decisions effective 1 December 2018 .....	3
Section H changes to Part II .....	4
Index .....	7

## Summary of decisions

EFFECTIVE 1 DECEMBER 2018

- Abiraterone acetate (Zytiga) tab 250 mg – amended restriction criteria
- Alendronate sodium (Fosamax) tab 40 mg – to be delisted 1 May 2019
- Amikacin (Biomed) inj 5 mg per ml, 5 ml syringe – price increase
- Bimatoprost (Bimatoprost Multichem) eye drops 0.03% – new listing and addition of HSS
- Bimatoprost (Bimatoprost Actavis) eye drops 0.03% – to be delisted 1 February 2019
- Calcium carbonate (Calsource) tab eff 1.75 g (1 g elemental) – to be delisted 1 July 2019
- Clomifene citrate (Serophene) tab 50 mg – to be delisted 1 March 2019
- Clozapine (Clozaril) tab 25 mg, 50 tab pack – listing new Pharmacode and delisting existing Pharmacode
- Diazepam (Stesolid) rectal tubes 5 mg – price increase
- Disulfiram (Antabuse) tab 200 mg – price increase
- Magnesium amino acid chelate cap 750 mg (150 mg elemental) – new listing and to be delisted 1 March 2019
- Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) – new listing and to be delisted 1 March 2019
- Metformin hydrochloride (Apotex) tab immediate-release 850 mg – new listing and addition of HSS
- Metformin hydrochloride (Metformin Mylan) tab immediate-release 850 mg – to be delisted 1 February 2019
- Lamotrigine (Logem) tab dispersible 25 mg, 50 mg and 100 mg – listing new Pharmacodes and delisting existing Pharmacodes
- Linezolid (Linezolid Kabi) inj 2 mg per ml, 300 ml bottle – new listing and addition of HSS
- Linezolid (Zyvox) inj 2 mg per ml, 300 ml bag – to be delisted 1 February 2019
- Pancreatic enzyme (Creon 10000) cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – listing new Pharmacode and delisting existing Pharmacode
- Paracetamol (Gacet) suppos 500 mg – new listing and addition of HSS
- Paracetamol (Paracare) suppos 500 mg – to be delisted 1 February 2019
- Testosterone (Androderm) patch 5 mg per day – price increase
- Ziprasidone (Zusdone) cap 20 mg – HSS reinstated

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 December 2018

### ALIMENTARY TRACT AND METABOLISM

10	METFORMIN HYDROCHLORIDE (Brand change) Tab immediate-release 850 mg – <b>1% DV Feb-19 to 2021</b> .....	7.04	500	<b>Apotex</b>
	Note – Metformin Mylan tab immediate-release 850 mg to be delisted 1 February 2019.			
10	PANCREATIC ENZYME (Pharmacode change) Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – <b>1% DV Sep-18 to 2021</b> .....	34.93	100	<b>Creon 10000</b>
	Note – this is a new Pharmacode listing 2535300; 954322 to be delisted from 1 May 2019.			
17	CALCIUM CARBONATE (delisting) Tab eff 1.75 g (1 g elemental).....	2.07	10	Calsource
	Note – Calsource tab eff 1.75 g (1 g elemental) to be delisted from 1 July 2019.			
18	MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE (new listing) Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) Note – magnesium oxide with with magnesium aspartate, magnesium amino acid chelate and magnesium citrate cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium) to be delisted from 1 March 2019.			
18	MAGNESIUM AMINO ACID CHELATE (new listing) Cap 750 mg (150 mg elemental) Note – magnesium amino acid chelate cap 750 mg (150 mg elemental) to be delisted from 1 March 2019.			

### HORMONE PREPARATIONS

62	TESTOSTERONE († price) Patch 5 mg per day .....	90.00	30	Androderm
65	CLOMIFENE CITRATE (delisting) Tab 50 mg .....	29.84	10	Serophene
	Note – Serophene tab 50 mg to be delisted from 1 March 2019.			

### INFECTIONS

72	AMIKACIN († price) → Inj 5 mg per ml, 5 ml syringe.....	181.50	10	Biomed
79	LINEZOLID (brand change) → Inj 2 mg per ml, 300 ml bottle – <b>1% DV Feb-19 to 2021</b> .....	18.50	1	<b>Linezolid Kabi</b>
	Note – Zyvox inj 2 mg per ml, 300 ml bag, 10 inj pack to be delisted 1 February 2019.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2018 (continued)

### MUSCULOSKELETAL SYSTEM

94	ALENDRONATE SODIUM (delisting) → Tab 40 mg.....	133.00	30	Fosamax
	Note – Fosamax tab 40 mg to be delisted from 1 May 2019.			

### NERVOUS SYSTEM

110	PARACETAMOL (brand change) Suppos 500 mg – <b>1% V Feb-19 to 2021</b> .....	12.40	50	<b>Gacet</b>
	Note – Paracare suppos 500 mg to be delisted from 1 February 2019.			
115	DIAZEPAM (↑ price) Rectal tubes 5 mg .....	40.87	5	Stesolid
116	LAMOTRIGINE (Pharmacode change) Tab dispersible 25 mg .....	19.38	56	Logem
	Tab dispersible 50 mg .....	32.97	56	Logem
	Tab dispersible 100 mg .....	56.91	56	Logem
	Note – new Pharmacode listings, tab dispersible 25 mg, 2553376; tab dispersible 50 mg, 2553384 and tab dispersible 100 mg, 2553392. Existing Pharmacodes to be delisted 1 June 2019.			
120	CLOZAPINE (Pharmacode change) Tab 25 mg .....	5.69	50	Clozaril
	Note – this is a new Pharmacode listing 2534843; 454680 to be delisted from 1 June 2019.			
121	ZIPRASIDONE (HSS reinstated) Cap 20 mg – <b>1% DV Dec-18 to 2021</b> .....	14.50	60	<b>Zusdone</b>
128	DISULFIRAM (↑ price) Tab 200 mg .....	55.00	100	Antabuse

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144	ABIRATERONE ACETATE (amended restriction criteria) → Tab 250 mg .....	4,276.19	120	Zytiga
	Restricted Initiation Medical oncologist, radiation oncologist or urologist <i>Re-assessment required after 5 6 months</i> All of the following: 1 Patient has prostate cancer; and 2 Patient has metastases; and 3 Patient's disease is castration resistant; and 4 Either: 4.1 All of the following: 4.1.1 Patient is symptomatic; and 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and 4.1.3 Patient has ECOG performance score of 0-1; and 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or 4.2 All of the following:			

*continued...*

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 December 2018 (continued)

continued...

- 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
- 4.2.2 Patient has ECOG performance score of 0-2; and
- 4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

*Re-assessment required after 5 6 months*

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

## SENSORY ORGANS

201	BIMATOPROST (brand change) Eye drops 0.03% – <b>1% DV Feb-19 to 2021</b> .....	3.30	3 ml	<b>Bimatoprost Multichem</b>
Note – Bimatoprost Actavis eye drops 0.03% to be delisted from 1 February 2019.				

# Index

## Pharmaceuticals and brands

### A

Abiraterone acetate .....	5
Alendronate sodium .....	5
Amikacin .....	4
Androderm .....	4
Antabuse .....	5

### B

Bimatoprost .....	6
Bimatoprost Multichem .....	6

### C

Calcium carbonate .....	4
Calsource .....	4
Clomifene citrate .....	4
Clozapine .....	5
Clozaril .....	5
Creon 10000 .....	4

### D

Diazepam .....	5
Disulfiram .....	5

### F

Fosamax .....	5
---------------	---

### G

Gacet .....	5
-------------	---

### L

Lamotrigine .....	5
Linezolid .....	4
Linezolid Kabi .....	4
Logem .....	5

### M

Magnesium amino acid chelate .....	4
Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate .....	4
Metformin hydrochloride .....	4

### P

Pancreatic enzyme .....	4
Paracetamol .....	5

### S

Serophene .....	4
Stesolid .....	5

### T

Testosterone .....	4
--------------------	---

### Z

Ziprasidone .....	5
Zusdone .....	5
Zytiga .....	5

New Zealand  
Permit No. 478

**Permit** 



**Pharmaceutical Management Agency**

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand  
Phone: 64 4 460 4990  
Fax: 64 4 460 4995  
Website: [www.pharmac.govt.nz](http://www.pharmac.govt.nz)  
Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

**ISSN 1172-9376 (Print)**

**ISSN 1179-3686 (Online)**

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand